Dr. Goy on the Potential Utility of Liso-Cel in MCL

Video

In Partnership With:

Andre H. Goy, MD, discusses the potential utility of lisocabtagene maraleucel in mantle cell lymphoma.

Andre H. Goy, MD, Physician in Chief Hackensack Meridian Health Oncology Care Transformation Service, Chairman & Chief Physician Officer - John Theurer Cancer Center, Lydia Pfund Chair for Lymphoma, Academic Chairman Oncology - Hackensack Meridian School of Medicine, Professor of Medicine – Georgetown University, Hackensack, NJ, discusses the potential utility of lisocabtagene maraleucel (liso-cel; Breyanzi) in mantle cell lymphoma (MCL).

During the 2020 ASH Annual Meeting and Exposition, findings from the phase 1 TRANSCEND-NHL-001 trial demonstrated an objective response rate of 84% and a complete response rate of 66% with liso-cel in 32 patients with relapsed/refractory MCL.

Moreover, compared with the results of the phase ZUMA-2 trial with brexucabtagene autoleucel (Tecartus), liso-cel appeared to demonstrate fewer cases of grade 3 or higher cytokine release syndrome and neurotoxicity, says Goy.

Although the CAR T-cell therapy is not approved to treat patients with relapsed/refractory MCL, liso-cel could provide another option that leads to durable responses in elderly patients with MCL who would otherwise have limited treatment options, concludes Goy.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Lori A. Leslie, MD, an expert on lymphoma